Form 4: Disc Medicine Director Granted Stock Options Valued at $50.86 Per Share

Disc Medicine, Inc. Director Donald William Nicholson was granted 10,000 stock options with an exercise price of $50.86 per share, aligning his interests with shareholder value.

Summary

• Donald William Nicholson, a Director of Disc Medicine, Inc. (IRON), was granted 10,000 stock options.
• The options have an exercise price of $50.86 per share.
• The transaction date for this grant was June 11, 2025.
• The options are scheduled to expire on June 10, 2035.
• Vesting of the shares underlying this option will occur upon the earlier of the Company's 2026 annual meeting of stockholders or the one-year anniversary of the grant date (June 11, 2026), contingent on Mr. Nicholson's continued service.

Sentiment

Score: 5

Explanation: The document reports a routine insider stock option grant, which is a neutral event in terms of immediate market sentiment, primarily serving to align director incentives with company performance.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The acquisition of options by a director can signal confidence in the company's future prospects.

Future Outlook

The stock options granted to Director Donald William Nicholson are subject to future vesting conditions, which will occur upon the earlier of the Company's 2026 annual meeting or the one-year anniversary of the grant date (June 11, 2026), provided continued service.

Management Comments

• The filing was signed by Rahul Khara, as Attorney-in-Fact for Donald William Nicholson.

Industry Context

This Form 4 filing represents a routine insider transaction, common across all industries, where a company grants equity compensation to its directors to incentivize performance and align their interests with shareholders. It does not provide specific insights into broader industry trends for the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice in corporate compensation across various industries, including biotechnology, to attract and retain talent and align interests.
• The specific size (10,000 options) and exercise price ($50.86) are specific to Disc Medicine, Inc. and its current valuation, and would typically be benchmarked against similar grants at peer companies of comparable size and stage within the biotech sector, though this document does not provide such comparative data.

Related Party Transactions

• The grant of stock options to Donald William Nicholson, a Director of Disc Medicine, Inc., constitutes a related party transaction, which is a standard form of equity compensation for board members.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's financial interests with long-term shareholder value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest upon the earlier of Disc Medicine's 2026 annual meeting or June 11, 2026, subject to Donald William Nicholson's continued service.

Key Dates

Keywords

Disc Medicine, IRON, Stock Option Grant, Director Compensation, Insider Transaction, SEC Form 4, Equity Incentive, Corporate Governance